Tag Archives: Marker Therapeutics Inc

Nomura Keeps a Buy Rating on Marker Therapeutics Inc (MRKR)

Nomura analyst Christopher Marai maintained a Buy rating on Marker Therapeutics Inc (MRKR – Research Report) on August 9 and set a price target of $16. The company’s shares closed last Monday at $4.50, close to its 52-week low of